News stories about MYOS RENS Technology (NASDAQ:MYOS) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. MYOS RENS Technology earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.0747014348943 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Separately, ValuEngine downgraded MYOS RENS Technology from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 12th.
MYOS RENS Technology (NASDAQ:MYOS) traded down 2.94% during trading on Friday, hitting $1.32. The company had a trading volume of 9,933 shares. The stock’s market capitalization is $7.71 million. The firm’s 50 day moving average is $1.73 and its 200-day moving average is $2.39. MYOS RENS Technology has a 52-week low of $1.02 and a 52-week high of $6.98.
MYOS RENS Technology Company Profile
MYOS RENS Technology Inc (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity.
What are top analysts saying about MYOS RENS Technology Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MYOS RENS Technology Inc. and related companies.